Effect of soy milk consumption on non-alcoholic fatty liver disease.
- Conditions
- on-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classified
- Registration Number
- IRCT201701162709N40
- Lead Sponsor
- Vice Chancellor for Research, Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion criteria : patient aged 18- 60 y ; diagnosis of NAFLD in accordance to American Gastroenterological Association guidelines as follows: a) hepatic steatosis confirmed by ultrasonography , b) there are no cause for secondary steatosis such as alcohol consumption, hereditary disorders( e.g. hemochromatosis,wilson’s disease) ,autoimmune diseaseses ,hepatotoxic drugs (e.g. methotrexate , amiodaron, tamoxifen, corticosteroids, valproate and anti-viral drugs) and chronic hepatitis C ; Absence of any other co-disorders including but not limited to other chronic liver diseases (hepatitis), cirrhosis, celiac, diabetes, thyroid disorders, breast cysts, as well as cardiovascular, renal, respiratory ,inflammatory and autoimmune diseases ; Absence of cancer or a history of cancer in patient and his/her first-degree relatives ; BMI of 25 to 40 (kg/m2) ; having no allergy to soy milk ; consuming no nutritional supplements during the last two months ; Taking no anti-inflammatory drugs; hasn’t any history of drug abuse and smoking; no pregnancy or lactation ; willingness to participate and sign an informed written consent.
Exclusion criteria: Lack of willingness to be a study participants during the study ; allergy or intolerance to soy milk during the study ; Lack of adherence to soy milk consumption ; existence of medical conditions that require special treatments during the study .
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method